Fabry Disease in Cerebrovascular Disease
Launched by CHANG GUNG MEMORIAL HOSPITAL · Aug 4, 2016
Trial Information
Current as of June 17, 2025
Unknown status
Keywords
ClinConnect Summary
This is a cross-sectional, population-based study to identify Fabry disease in patients with early cerebrovascular involvement. Eligible patients are age above 18 years old (\<=55 years old) with early cerebrovascular involvement and have provided inform consent. Patients who have been diagnosed Fabry disease are not eligible.
The present study will use samples of early cerebrovascular involvement patients which have been enrolled in two previous IRB approved projects \[103-3254C (origin 98-3889A3), 100-4008C (origin 97-0470B)\], participants of both studies have consented that participant...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age \>= 18 y/o
- • Both females and males who have ischemic or hemorrhagic stroke before the age of 55 y/o
- • Patient or his/her legal representatives are willing to sign the informed consent
- Exclusion Criteria:
- • Ischemic or hemorrhagic stroke patients who are already diagnosed to have Fabry disease
About Chang Gung Memorial Hospital
Chang Gung Memorial Hospital, one of the largest healthcare organizations in Taiwan, is renowned for its commitment to advancing medical research and improving patient care. As a clinical trial sponsor, the hospital leverages its extensive clinical expertise and state-of-the-art facilities to conduct innovative research across various medical disciplines. With a focus on collaboration and ethical practices, Chang Gung Memorial Hospital aims to contribute to the global body of medical knowledge through rigorous clinical trials that enhance treatment options and improve health outcomes for patients.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Kweishan, Taoyuan, Taiwan
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials